Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, Duffin KL, Robins DA, Haupt A

Diabetes care14 Apr 2020Cited by 283 (Europe PMC)

PMID32291277PMCIDPMC7245348DOI10.2337/dc19-1892PepBankPUB-32291277

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, alanine aminotransferase (ALT) fell significantly from baseline at 26 weeks in all treatment groups.
In plain wordsIn people with type 2 diabetes, the liver enzyme ALT fell from its starting level in every treatment group.
Peptide
Tirzepatide
Outcome
DecreaseALT change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
1, 5, 10 or 15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant (P < 0.05) reductions from baseline in ALT (all groups), AST (all groups except tirzepatide 10 mg), K-18 (tirzepatide 5, 10, 15 mg), and Pro-C3 (tirzepatide 15 mg) were observed at 26 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127701
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, aspartate aminotransferase (AST) fell significantly from baseline at 26 weeks in all treatment groups except tirzepatide 10 mg.
In plain wordsIn people with type 2 diabetes, the liver enzyme AST fell from its starting level in all groups except the tirzepatide 10 mg group.
Peptide
Tirzepatide
Outcome
DecreaseAST change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
1, 5, 10 or 15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant (P < 0.05) reductions from baseline in ALT (all groups), AST (all groups except tirzepatide 10 mg), K-18 (tirzepatide 5, 10, 15 mg), and Pro-C3 (tirzepatide 15 mg) were observed at 26 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127702
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the biomarker keratin-18 (K-18) fell significantly from baseline at 26 weeks with tirzepatide 5, 10 and 15 mg.
In plain wordsIn type 2 diabetes, a fatty liver disease marker (K-18) fell from its starting level with tirzepatide 5, 10 and 15 mg.
Peptide
Tirzepatide
Outcome
DecreaseKeratin-18 (K-18) change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
5 mg, 10 mg or 15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant (P < 0.05) reductions from baseline in ALT (all groups), AST (all groups except tirzepatide 10 mg), K-18 (tirzepatide 5, 10, 15 mg), and Pro-C3 (tirzepatide 15 mg) were observed at 26 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127703
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the biomarker procollagen III (Pro-C3) fell significantly from baseline at 26 weeks with tirzepatide 15 mg.
In plain wordsIn people with type 2 diabetes, a fatty liver disease marker (Pro-C3) fell from its starting level with tirzepatide 15 mg.
Peptide
Tirzepatide
Outcome
DecreaseProcollagen III (Pro-C3) change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant (P < 0.05) reductions from baseline in ALT (all groups), AST (all groups except tirzepatide 10 mg), K-18 (tirzepatide 5, 10, 15 mg), and Pro-C3 (tirzepatide 15 mg) were observed at 26 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127704
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, ALT decreases with tirzepatide 10 mg and 15 mg were significant compared with dulaglutide at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 mg and 15 mg lowered the liver enzyme ALT more than dulaglutide did.
Peptide
Tirzepatide
Outcome
DecreaseALT decrease vs dulaglutide
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Liver fat and liver function · Liver
Studied dose
10 mg or 15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127705
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the decrease in K-18 with tirzepatide 10 mg was significant compared with placebo at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 mg lowered a fatty liver disease marker (K-18) more than placebo did.
Peptide
Tirzepatide
Outcome
DecreaseK-18 decrease vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
10 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127706
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the decrease in Pro-C3 with tirzepatide 15 mg was significant compared with placebo at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide 15 mg lowered a fatty liver disease marker (Pro-C3) more than placebo did.
Peptide
Tirzepatide
Outcome
DecreasePro-C3 decrease vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127707
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, adiponectin increased significantly from baseline with tirzepatide 10 mg and 15 mg compared with placebo at 26 weeks.
In plain wordsIn people with type 2 diabetes, tirzepatide 10 mg and 15 mg raised adiponectin levels more than placebo did.
Peptide
Tirzepatide
Outcome
IncreaseAdiponectin increase vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
10 mg or 15 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Adiponectin significantly increased from baseline with tirzepatide compared with placebo (10, 15 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127708
09HumanOther designEfficacy outcome
In patients with type 2 diabetes, dulaglutide produced a smaller ALT decrease than tirzepatide 10 mg.
In plain wordsIn patients with diabetes, dulaglutide reduced ALT less than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseALT versus tirzepatide 10 mg
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Liver fat and liver function · Liver
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127709
10HumanOther designEfficacy outcome
In patients with type 2 diabetes, dulaglutide produced a smaller ALT decrease than tirzepatide 15 mg.
In plain wordsIn patients with diabetes, dulaglutide reduced ALT less than tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseALT versus tirzepatide 15 mg
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Liver fat and liver function · Liver
Studied dose
1.5 mg weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Report a problemFND-3229127710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT03131687

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 31824 May 2017 to 1 Aug 2018

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 20 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 12:39 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.